Squarepoint Ops LLC Acquires Shares of 43,640 Ikena Oncology, Inc. (NASDAQ:IKNA)

Squarepoint Ops LLC acquired a new stake in Ikena Oncology, Inc. (NASDAQ:IKNA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 43,640 shares of the company’s stock, valued at approximately $72,000. Squarepoint Ops LLC owned about 0.09% of Ikena Oncology at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BML Capital Management LLC raised its stake in shares of Ikena Oncology by 395.8% in the 4th quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock valued at $5,881,000 after purchasing an additional 2,862,578 shares in the last quarter. Gilead Sciences Inc. acquired a new stake in shares of Ikena Oncology in the 4th quarter valued at about $3,294,000. Peapod Lane Capital LLC acquired a new stake in shares of Ikena Oncology in the 4th quarter valued at about $833,000. Geode Capital Management LLC raised its stake in shares of Ikena Oncology by 21.0% in the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company’s stock valued at $538,000 after purchasing an additional 56,936 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company’s stock valued at $255,000 after purchasing an additional 154,892 shares in the last quarter. 75.00% of the stock is owned by hedge funds and other institutional investors.

Ikena Oncology Stock Down 1.4%

IKNA opened at $1.45 on Wednesday. The firm has a market cap of $69.97 million, a price-to-earnings ratio of -1.18 and a beta of 0.45. Ikena Oncology, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $1.94. The company’s 50-day moving average price is $1.18 and its 200 day moving average price is $1.39.

Ikena Oncology (NASDAQ:IKNA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.03. Research analysts anticipate that Ikena Oncology, Inc. will post -0.91 earnings per share for the current year.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.